Related Experiment Video

Updated: Mar 29, 2026

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

1.3K

Memantine for the treatment of frontotemporal dementia: a meta-analysis

Taro Kishi1, Shinji Matsunaga1, Nakao Iwata1

  • 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.

Neuropsychiatric Disease and Treatment
|December 10, 2015
PubMed
Abstract

Insights

Memantine may offer slight benefits for frontotemporal dementia (FTD) patients, but evidence is limited. Further research with larger sample sizes is needed to confirm memantine

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Frontotemporal dementia (FTD) lacks conclusive evidence for memantine efficacy.
  • A meta-analysis was conducted to evaluate memantine's efficacy and tolerability in FTD.

Purpose of the Study:

  • To conduct a comprehensive meta-analysis on memantine's efficacy and tolerability in frontotemporal dementia (FTD).

Main Methods:

  • Searched PubMed, Cochrane Library, and PsycINFO databases up to April 2015.
  • Analyzed Clinical Global Impression, Mini-Mental State Examination, Neuropsychiatric Inventory, Zarit Burden Interview scores, and all-cause discontinuation.
  • Calculated standardized mean difference and risk ratio with 95% confidence intervals.

Main Results:

  • Two RCTs (n=130) met inclusion criteria.
  • Memantine showed marginal superiority over placebo in Clinical Global Impression scores (SMD=-0.34, P=0.06).
  • No significant differences were found for other cognitive, neuropsychiatric, or tolerability outcomes.

Conclusions:

  • Memantine may offer potential benefits for FTD patients.
  • Current evidence is based on only two RCTs.
  • Larger sample size studies are required to validate these findings.
Keywords:
Clinical Global Impressionfrontotemporal dementiamemantinemeta-analysis

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-145105:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
833
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
676
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K